Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 11/20 | 0.56 |
| ▸ | NR3C1 | P04150 | 19/20 | 0.52 |
| ▸ | PGR | P06401 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1492607 | 0.83 | NR3C2 (0.53) | NR3C2NR3C1 | |
| SCHEMBL1634784 | 0.81 | NR3C2 (0.53) | NR3C2NR3C1 | |
| SCHEMBL3882399 | 0.79 | NR3C2 (0.53) | NR3C2NR3C1PGR | |
| SCHEMBL4490249 | 0.78 | NR3C2 (0.51) | NR3C2NR3C1 | |
| SCHEMBL13823431 | 0.77 | NR3C2 (0.50) | NR3C2NR3C1 | |
| SCHEMBL3889197 | 0.77 | NR3C2 (0.53) | NR3C2NR3C1PGR | |
| SCHEMBL10313421 | 0.77 | NR3C2 (0.50) | NR3C2NR3C1 | |
| SCHEMBL4483389 | 0.76 | NR3C2 (0.49) | NR3C2NR3C1 | |
| SCHEMBL5203357 | 0.76 | NR3C2 (0.49) | NR3C2NR3C1 | |
| SCHEMBL1633791 | 0.76 | NR3C1 (0.49) | NR3C2NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186864-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7138411-B2 | Substituted benzopyran derivatives for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7074806-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-20060014787-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-01-19 | — | — | US | disclosed |
| EP-1513810-A1 | 4-(ARYL OR HETEROARYL) -2-BUTYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-03-16 | — | — | EP | disclosed |
| EP-1511716-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040038977-A1 | Substituted bezopyran derivatives for the treatment of inflammation | G.D. SEARLE & CO. | 2004-02-26 | — | — | US | disclosed |
| US-20040010148-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| US-20040010020-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-01-15 | — | — | US | disclosed |
| WO-2003104195-A1 | 4-(ARYL OR HETEROARYL) -2-BUTYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003101932-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010020-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | NR3C2 2/4885NR3C1 1/4885PGR 179/4885 |
| US-20040038977-A1 | Substituted bezopyran derivatives for the treatment of inflammation | PTGS1, PTGES2, IL1R1 | NR3C2 180/4885NR3C1 71/4885PGR 1024/4885 |
| US-20060014787-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, MC2R, NR3C2 | NR3C2 3/4885NR3C1 1/4885PGR 77/4885 |
| US-20040010148-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | NR3C2 2/4885NR3C1 1/4885PGR 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.